MedTrace Logo

EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC

NCT07637448 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-06-09

No results posted yet for this study

Summary

This study is an open-label, multicenter, single-arm clinical study.

Conditions

  • Lung Cancer Non-Small Cell Cancer (NSCLC)
  • EGFR Activating Mutation
  • PD-1 Antibody

Interventions

DRUG

EGFR-TKIs Combined with PD-1 Monoclonal Antibody

EGFR-TKIs Combined with PD-1 Monoclonal Antibody

Sponsors & Collaborators

  • Nanfang Hospital, Southern Medical University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-21
Primary Completion
2029-03-01
Completion
2030-03-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07637448 on ClinicalTrials.gov